Free weekly newsletter

Get the free weekly executive digest

The new leadership moves, who’s behind them, and what they mean — delivered to your inbox every week. No credit card, unsubscribe anytime.

Weekly Digest

New leadership moves, summarized for you

Straight to Inbox

No login, no app to check — it comes to you

Leadership Trends

See who's moving and how much in your market

No credit card required Weekly executive digest

Aurelia Caparrós Appointed As Chief Business Officer of Amarna Therapeutics

PRIVATEApr 19, 2024•about 2 years ago

Position

Chief Business Officer

Company

Amarna Therapeutics

Aurelia Caparrós

LeidenBiotechnologyHealth CareScience And Engineering

Description

Aurelia Caparrós has been appointed as the new Chief Business Officer (CBO) of Amarna Therapeutics, effective 1st of April 2024. Bringing more than 25 years of healthcare industry experience with expertise in business development, strategy, and global marketing, she will be responsible for driving Amarna's future growth and expansion both in the Netherlands and Spain, and her key responsibilities will include identifying assets, companies, and areas of interest, designing tailored partnering structures, and securing attractive deals through the entire deal-making process.

Company Information

Company

Amarna Therapeutics

Location

Leiden, South Holland, Netherlands

About

Amarna Therapeutics is a privately held, pre-clinical biotech company developing transformative, potentially curative gene therapies for a range of rare and prevalent diseases. The company is pioneering the development of gene therapies based on simian virus 40 (SV40), a macaque polyoma virus to which humans are immunologically naïve. Amarna has created a proprietary production cell line (SuperVero) that for the first time makes it possible to produce SV40-derived vectors suitable for therapeutic use. The company's fully integrated gene therapy platform combining SuperVero with its genetically engineered SVec viral vector is truly unique in its intrinsic capability to deliver transgenes without eliciting immune responses to the vector nor to the transgene product. Leveraging this 'natural' non-immunogenicity feature of its gene delivery system in humans, Amarna is developing a broad pipeline of safe effective and durable gene therapies focused on genetic disorders, autoimmune diseases and chronic inflammation. Founded in 2008, Amarna's head office is based in Leiden Bio Science Park, the Netherlands, with a research subsidiary located in Seville, Spain.

Related People

Suggested for you

Choose your plan to reveal verified contacts

Predictive Intelligence

Strategic

ML-powered predictions for Amarna Therapeutics's next move

Learn about Strategic plan

Executive Insights

Based on hiring data

New executive impact window

87% of new executives make significant technology decisions within first 100 days

Budget influence

C-level executives control 73% of technology spending decisions

Transformation catalyst

65% of new senior hires launch digital transformation initiatives

Vendor review timeline

New executives typically review existing vendors within 6 months